Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies

详细信息    查看全文

• 作者：Natascia Brondino ; Laura Fusar-Poli…
• 关键词：Autism spectrum disorder ; GABA ; Clinical trials ; Systematic review
• 刊名：Journal of Autism and Developmental Disorders
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：46
• 期：3
• 页码：825-839
• 全文大小：753 KB
• 参考文献：Abrahams, B. S., & Geschwind, D. H. (2008). Advances in autism genetics: On the threshold of a new neurobiology. Nature Reviews Genetics, 9, 341–355.PubMedCentral CrossRef PubMed
  Abu Shmais, G. A., Al-Ayadhi, L. Y., Al-Dbass, A. M., & El-Ansary, A. K. (2012). Mechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autism. Journal of Neurodevelopmental Disorders, 4(1), 4.PubMedCentral CrossRef PubMed
  Alabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014). Association of social and cognitive impairment and biomarkers in autism spectrum disorders. Journal of Neuroinflammation, 8(11), 4.CrossRef
  Amaral, D. G., Schumann, C. M., & Nordahl, C. W. (2008). Neuroanatomy of autism. Trends in Neurosciences, 31, 137–145.CrossRef PubMed
  Banerjee, A., García-Oscos, F., Roychowdhury, S., Galindo, L. C., Hall, S., Kilgard, M. P., et al. (2013). Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. International Journal of Neuropsychopharmacology, 16, 1309–1810.PubMedCentral CrossRef PubMed
  Bauman, M. L., & Kemper, T. L. (2005). Neuroanatomic observations of the brain in autism: A review and future directions. International Journal of Developmental Neuroscience, 23, 183–187.CrossRef PubMed
  Berg, A. T., Plioplys, S., & Tuchman, R. (2011). Risk and correlates of autism spectrum disorders in children with epilepsy: A community based study. Journal of Child Neurology, 26, 540–547.PubMedCentral CrossRef PubMed
  Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science Translational Medicine, 4(152), 152ra127.CrossRef PubMed
  Blatt, G. J., Fitzgerald, C. M., Guptill, J. T., Booker, A. B., Kemper, T. L., & Bauman, M. L. (2001). Density and distribution of hippocampal neurotransmitter receptors in autism: An autoradiographic study. Journal of Autism and Developmental Disorders, 31, 537–543.CrossRef PubMed
  Brogden, R. N., & Goa, K. L. (1991). Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine. Drugs, 42, 1061–1089.CrossRef PubMed
  Bu, D. F., Erlander, M. G., Hitz, B. C., Tillakaratne, N. J., Kaufman, D. L., Wagner-McPherson, C. B., et al. (1992). Two human glutamate decarboxylase, 65 kDa GAD and 67 kDa GAD, are each encoded by a single gene. Proceedings of the National Academy of Sciences of the United States of America, 89, 2115–2119.PubMedCentral CrossRef PubMed
  Buxbaum, J. D., Silverman, J. M., Smith, C. J., Greenberg, D. A., Kilifarski, M., Reichert, J., et al. (2002). Association between a GABRB3 polymorphism and autism. Molecular Psychiatry, 7, 311–316.CrossRef PubMed
  Casanova, M. F., van Kooten, I. A., Switala, A. E., van Engeland, H., Heinsen, H., Steinbusch, H. W., et al. (2006). Minicolumnar abnormalities in autism. Acta Neuropathologica, 112(3), 287–303.CrossRef PubMed
  CDC. (2014). Prevalence of autism spectrum disorders among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR, 63(SS02), 1–21.
  Cellot, G., & Cherubini, E. (2014). GABAergic signaling as therapeutic target for autism spectrum disorders. Frontiers in Pediatrics, 8(2), 70.
  Chakrabarti, S., & Fombonne, E. (2005). Pervasive developmental disorders in preschool children: Confirmation of high prevalence. American Journal of Psychiatry, 162, 1133–1141.CrossRef PubMed
  Cheh, M. A., Millonig, J. H., Roselli, L. M., Ming, X., Jacobsen, E., Kamdar, S., et al. (2006). En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. Brain Research, 1116, 166–176.CrossRef PubMed
  Chez, M. G., Buchanan, C. P., Aimonovitch, M. C., Becker, M., Schaefer, K., Black, C., et al. (2002). Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. Journal of Child Neurology, 17, 833–837.CrossRef PubMed
  Coghlan, S., Horder, J., Inkster, B., Mendez, M. A., Murphy, D. G., & Nutt, D. J. (2012). GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neuroscience and Biobehavioral Reviews, 36(9), 2044–2055.PubMedCentral CrossRef PubMed
  DeLorey, T. M., Sahbaie, P., Hashemi, E., Homanics, G. E., & Clark, J. D. (2008). Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: A potential model of autism spectrum disorder. Behavioural Brain Research, 187, 207–220.PubMedCentral CrossRef PubMed
  Dhossche, D., Applegate, H., Abraham, A., Maertens, P., Bland, L., Bencsath, A., et al. (2002). Elevated plasma gammaaminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. Medical Science Monitor, 8, R1–R6.
  Eftekhari, S., Mehvari Habibabadi, J., Najafi Ziarani, M., Hashemi Fesharaki, S. S., Gharakhani, M., Mostafavi, H., et al. (2013). Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia, 54(1), e9–e12.CrossRef PubMed
  El-Ansary, A., & Al-Ayadhi, L. (2014). GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. Journal of Neuroinflammation, 11(1), 189.PubMedCentral CrossRef PubMed
  El-Ansary, A. K., Bacha, A. B., & Ayahdi, L. Y. (2011). Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clinical Biochemistry, 44(13), 1116–1120.CrossRef PubMed
  Erickson, C. A., Early, M., Stigler, K. A., Wink, L. K., Mullett, J. E., & McDougle, C. J. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21, 565–569.PubMedCentral CrossRef PubMed
  Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010). Brief report: Acamprosate in fragile X syndrome. Journal of Autism and Developmental Disorders, 40, 1412–1416.CrossRef PubMed
  Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., et al. (2014a). STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study. Journal of Autism and Developmental Disorders, 44(4), 958–964.CrossRef PubMed
  Erickson, C. A., Wink, L. K., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V., et al. (2014b). Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. Journal of Autism and Developmental Disorders, 44, 981–987.CrossRef PubMed
  Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., et al. (2013). Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology (Berlin), 228, 75–84.CrossRef
  Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009a). Expression of GABAB receptors is altered in brains of subjects with autism. Cerebellum, 8, 64–69.PubMedCentral CrossRef PubMed
  Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002). Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in parietal and cerebellar cortices of autistic subjects. Biological Psychiatry, 52, 805–810.CrossRef PubMed
  Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rooney, R. J., Patel, D. H., & Thuras, P. D. (2010). mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. Journal of Autism and Developmental Disorders, 40, 743–750.PubMedCentral CrossRef PubMed
  Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rustan, O. G., Rooney, R. J., & Thuras, P. D. (2014). Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in the superior frontal cortex of subjects with autism. Journal of Autism and Developmental Disorders, 44(8), 1833–1845.CrossRef PubMed
  Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009b). GABA (A) receptor down regulation in brains of subjects with autism. Journal of Autism and Developmental Disorders, 39, 223–230.PubMedCentral CrossRef PubMed
  Földy, C., Malenka, R. C., & Südhof, T. C. (2013). Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron, 78, 498–509.PubMedCentral CrossRef PubMed
  Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006). Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. Pediatrics, 118, e139–e150.CrossRef PubMed
  Frizzo, M. E., Dall’Onder, L. P., Dalcin, K. B., & Souza, D. O. (2004). Riluzole enhances glutamate uptake in rat astrocyte cultures. Cellular and Molecular Neurobiology, 24(1), 123–128.CrossRef PubMed
  Ghaleiha, A., Mohammadi, E., Mohammadi, M. R., Farokhnia, M., Modabbernia, A., Yekehtaz, H., et al. (2013). Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial. Paediatric Drugs, 15(6), 505–514.CrossRef PubMed
  Guptill, J. T., Booker, A. B., Gibbs, T. T., Kemper, T. L., Bauman, M. L., & Blatt, G. J. (2007). [3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: A multiple concentration autoradiographic study. Journal of Autism and Developmental Disorders, 37, 911–920.CrossRef PubMed
  Hadjikhani, N., Zürcher, N. R., Rogier, O., Ruest, T., Hippolyte, L., Ben-Ari, Y., et al. (2015). Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study. Autism, 19(2), 149–157.CrossRef PubMed
  Harada, M., Taki, M. M., Nose, A., Kubo, H., Mori, K., Nishitani, H., et al. (2011). Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument. Journal of Autism and Developmental Disorders, 41, 447–454.CrossRef PubMed
  He, Y., Benz, A., Fu, T., Wang, M., Covey, D. F., Zorumski, C. F., et al. (2002). Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology, 42(2), 199–209.CrossRef PubMed
  Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15(4), 682–692.CrossRef PubMed
  Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science Translational Medicine, 4(152), 152ra128.CrossRef PubMed
  Higgins, J. P. T., & Green, S. (Eds.). (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
  Hogart, A., Nagarajan, R. P., Patzel, K. A., Yasui, D. H., & Lasalle, J. M. (2007). 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Human Molecular Genetics, 16, 691–703.PubMedCentral CrossRef PubMed
  Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35, 990–998.PubMedCentral CrossRef PubMed
  Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology, 9, 209–213.CrossRef PubMed
  Hussman, J. P. (2001). Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. Journal of Autism and Developmental Disorders, 31, 247–248.CrossRef PubMed
  Kalk, N. J., & Lingford-Hughes, A. R. (2014). The clinical pharmacology of acamprosate. British Journal of Clinical Pharmacology, 77(2), 315–323.PubMedCentral CrossRef PubMed
  Kaupmann, K., Schuler, V., Mosbacher, J., Bischoff, S., Bittiger, H., Heid, J., et al. (1998). Human γ-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels. Proceedings of the National Academy of Sciences of the United States of America, 95, 14991–14996.PubMedCentral CrossRef PubMed
  Kim, H. L., Donnelly, J. H., Tournay, A. E., Book, T. M., & Filipek, P. (2006a). Absence of seizures despite high prevalence of epileptiform EEG abnormalities in children with autism monitored in a tertiary care center. Epilepsia, 47(2), 394–398.CrossRef PubMed
  Kim, S. A., Kim, J. H., Park, M., Cho, I. H., & Yoo, H. J. (2006b). Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology, 54, 160–165.CrossRef PubMed
  Kuriyama, K., Hirouchi, M., & Kimura, H. (2000). Neurochemical and molecular pharmacological aspects of the GABA(B) receptor. Neurochemical Research, 25, 1233–1239.CrossRef PubMed
  Lal, R., Sukbuntherng, J., Tai, E. H., Upadhyay, S., Yao, F., Warren, M. S., et al. (2009). Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. Journal of Pharmacology and Experimental Therapeutics, 330(3), 911–921.CrossRef PubMed
  Lawrence, Y. A., Kemper, T. L., Bauman, M. L., & Blatt, G. J. (2010). Parvalbumin-, calbindin-, and calretinin-immunoreactive hippocampal interneuron density in autism. Acta Neurologica Scandinavica, 121, 99–108.CrossRef PubMed
  Lemonnier, E., & Ben-Ari, Y. (2010). The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatrica, 99, 1885–1888.CrossRef PubMed
  Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., et al. (2012). A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry, 2, e202.PubMedCentral CrossRef PubMed
  Levy, S. E., Mandell, D. S., & Schultz, R. T. (2009). Autism. The Lancet, 374, 1627–1638.CrossRef
  Löscher, W. (1981). Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. Journal of Neurochemistry Research, 36, 1521–1527.CrossRef
  Löscher, W. (2002). Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 16(10), 669–694.CrossRef PubMed
  Ma, D. Q., Whitehead, P. L., Menold, M. M., Martin, E. R., Ashley-Koch, A. E., Mei, H., et al. (2005). Identification of significant association and gene–gene interaction of GABA receptor subunit genes in autism. American Journal of Human Genetics, 77, 377–388.PubMedCentral CrossRef PubMed
  Martin, D., Thompson, M. A., & Nadler, J. V. (1993). The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. European Journal of Pharmacology, 250(3), 473–476.CrossRef PubMed
  Mendez, M. A., Horder, J., Myers, J., Coghlan, S., Stokes, P., Erritzoe, D., et al. (2013). The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology, 68, 195–201.PubMedCentral CrossRef PubMed
  Mori, T., Mori, K., Fujii, E., Toda, Y., Miyazaki, M., Harada, M., et al. (2012). Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Development, 34, 648–654.CrossRef PubMed
  Mott, D. D., & Lewis, D. V. (1994). The pharmacology and function of central GABAB receptors. International Review of Neurobiology, 36, 97–223.CrossRef PubMed
  NCT01288716. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01288716
  NCT01706523. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01706523
  NCT01813318. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01813318
  NCT01966679.https://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01966679
  NCT02094651. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT02094651
  Nutt, D. J., & Malizia, A. L. (2001). New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry, 179, 390–396.CrossRef PubMed
  Oblak, A., Gibbs, T. T., & Blatt, G. J. (2009). Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Research, 2, 205–219.PubMedCentral CrossRef PubMed
  Pizzarelli, R., & Cherubini, E. (2013). Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of autism. Frontiers in Cellular Neuroscience, 4(7), 85.
  Rimvall, K., & Martin, D. L. (1994). The level of GAD67 protein is highly sensitive to small increases in intraneuronal γ-aminobutyric acid levels. Journal of Neurochemistry, 62, 1375–1381.CrossRef PubMed
  Ritvo, E. R., Freeman, B. J., Scheibel, A. B., Duong, T., Robinson, H., Guthrie, D., et al. (1986). Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLANSAC autopsy research report. American Journal of Psychiatry, 146, 862–866.
  Rojas, D. C., Singel, D., Steinmetzm, S., Hepburn, S., & Brown, M. S. (2014). Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. Neuroimage, 86, 28–34.PubMedCentral CrossRef PubMed
  Rolf, L. H., Haarmann, F. Y., Grotemeyer, K. H., & Kehrer, H. (1993). Serotonin and amino acid content in platelets of autistic children. Acta Psychiatrica Scandinavica, 87, 312–316.CrossRef PubMed
  Russo, A. J. (2013). Correlation between hepatocyte growth factor (HGF) and gamma-aminobutyric acid (GABA) plasma levels in autistic children. Biomark Insights, 12(8), 69–75.CrossRef
  Sawaya, M. C. B., Horton, R. W., & Meldrun, B. S. (1975). Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia, 16, 649–655.CrossRef PubMed
  Sgadò, P., Genovesi, S., Kalinovsky, A., Zunino, G., Macchi, F., Allegra, M., et al. (2013). Loss of GABAergic neurons in the hippocampus and cerebral cortex of engrailed-2 null mutant mice: Implications for autism spectrum disorders. Experimental Neurology, 247, 496–505.PubMedCentral CrossRef PubMed
  Sieghart, W., & Sperk, G. (2002). Subunit composition, distribution and function of GABA(A) receptor subtypes. Current Topics in Medicinal Chemistry, 2, 795–816.CrossRef PubMed
  Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M., & Mody, I. (2003). Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proceedings of the National Academy of Sciences of the United States of America, 100(24), 14439–14444.PubMedCentral CrossRef PubMed
  Tabuchi, K., Blundell, J., Etherton, M. R., Hammer, R. E., Liu, X., Powell, C. M., et al. (2007). A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science, 318, 71–76.PubMedCentral CrossRef PubMed
  Trombley, P. Q., Horning, M. S., & Blakemore, L. J. (1998). Carnosine modulates zinc and copper effects on amino acid receptors and synaptic transmission. NeuroReport, 9(15), 3503–3507.CrossRef PubMed
  Tuchman, R., & Rapin, I. (2002). Epilepsy in autism. Lancet Neurology, 1(6), 352–358.CrossRef PubMed
  van Kooten, I. A., Palmen, S. J., von Cappeln, P., Steinbusch, H. W., Korr, H., Heinsen, H., et al. (2008). Neurons in the fusiform gyrus are fewer and smaller in autism. Brain, 131, 987–999.CrossRef PubMed
  Veenstra-VanderWeele, J., Sikich, L., Melmed, R., von Hehn, J. S., Walton-Bowen, K. L., & Kuriyama, N. et al. (2013). Randomized, controlled, phase 2 trial of STX209 for social function in ASD. Abstract presented at the IMFAR meeting 2013.
  Weiss, M., Tikhonov, D., & Buldakova, S. (2002). Effect of flumazenil on GABAA receptors in isolated rat hippocampal neurons. Neurochemical Research, 7(12), 1605–1612.CrossRef
  Wolpert, C. M., Menold, M. M., Bass, M. P., Qumsiyeh, M. B., Donnelly, S. L., Ravan, S. A., et al. (2000). Three probands with autistic disorder and isodicentric chromosome 15. American Journal of Medical Genetics, 96, 365–372.CrossRef PubMed
  Wray, J. A., Yoon, J. H., Vollmer, T., & Mauk, J. (2000). Pilot study of the behavioral effects of flumazenil in two children with autism. Journal of Autism and Developmental Disorders, 30, 619–620.CrossRef PubMed
  Yip, J., Soghomonian, J. J., & Blatt, G. J. (2007). Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: Pathophysiological implications. Acta Neuropathologica, 113, 559–568.CrossRef PubMed
  Yip, J., Soghomonian, J. J., & Blatt, G. J. (2009). Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: An in situ hybridization study. Autism Research, 2, 50–59.PubMedCentral CrossRef PubMed
  
• 作者单位：Natascia Brondino (1)
  Laura Fusar-Poli (1)
  Cristina Panisi (1)
  Stefano Damiani (1)
  Francesco Barale (1)
  Pierluigi Politi (1)
  
  1. Department of Brain and Behavioral Sciences, University of Pavia, Via Bassi 21, 27100, Pavia, Italy
  
• 刊物类别：Behavioral Science
• 刊物主题：Psychology
  Child and School Psychology
  Pediatrics
  
• 出版者：Springer Netherlands
• ISSN：1573-3432

文摘

Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings. Keywords Autism spectrum disorder GABA Clinical trials Systematic review